Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2026)

Harmony Biosciences Holdings has disclosed EBITDA across 8 years of filings, most recently posting $31.7 million for Q1 2026.

• EBITDA for Q1 2026 came in at $31.7 million, down 30.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $145.0 million (down 5.34% YoY), and the FY2025 annual result was $159.0 million, up 9.21% from the prior year.
• EBITDA came in at $31.7 million for Q1 2026 at Harmony Biosciences Holdings, up from $22.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $87.8 million in Q3 2022 to a low of $11.5 million in Q2 2024.
• The 5-year median for EBITDA is $38.2 million (2024), against an average of $38.0 million.
• Across the five-year window, EBITDA surged 1012.62% in 2022 and slumped 65.9% in 2024, its largest moves.
• Harmony Biosciences Holdings' EBITDA stood at $48.5 million in 2022, then slumped by 44.11% to $27.1 million in 2023, then surged by 80.8% to $49.0 million in 2024, then plunged by 54.17% to $22.5 million in 2025, then jumped by 41.17% to $31.7 million in 2026.
• The last three EBITDA figures came in at $31.7 million (Q1 2026), $22.5 million (Q4 2025), and $51.0 million (Q3 2025), per Business Quant data.